Related Experiment Video
Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Development
Youssef M Seddeik1, Muataz El-Barbari1, Mohamed Nasim1
1Faculty of Medicine Port Said Univeristy, Egypt, Port Said, Port Said, Egypt.
Background:
Alzheimer's disease (AD) is a neurodegenerative disease and one of the main causes of dementia posing a significant global burden. The anti-Aβ monoclonal antibody (mAb) solanezumab was used in the treatment of early AD in recent trials and have produced mixed cognitive and clinical results. The purpose of this systematic review and meta-analysis is to investigate the effect of solanezumab on cognitive functions and biomarkers levels in RCTs on AD patients.
Methods:
A systematic search was conducted up to December 2024 across databases such as PubMed, Scopus, Web of Science, Cochrane library and ClinicalTrials.gov for RCTs. The quality of studies was assessed using the Cochrane risk of bias 2 tool. RevMan 5.3 was used for statistical analysis. Cognitive functions included in meta-analysis were MMSE, ADAS-Cog14, and CDR-SB. Biomarkers included in meta-analysis were CSF free AB1-40, CSF free AB1-42, and CSF Tau levels.
Results:
Six randomized clinical trials with a total of 5472 enrolled participants were included. All Biomarkers levels demonstrated negative outcomes for the solanezumab group compared to the placebo group; CSF free AB1-40, CSF free AB1-42 and CSF Tau showed standardized mean difference of -0.40[-0.71, -.0.09], -0.11[-0.19, -0.03] and -0.01[-0.26, 0.24] respectively, indicating that solanezumab does not provide clinically significant results. Solanezumab mostly showed statistically significant improvement, although limited, across cognitive tests including MMSE and ADAS-Cog14 -0.08[-0.14, -0.02] and 0.13 [0.05, 0.22] respectively, while CDR-SB test didn't favor either groups -0.04[-0.14, 0.05].
Conclusion:
Despite solanezumab worsening biomarkers levels, the data suggests that solanezumab has a limited efficacy to improve the cognitive function of participants with early AD.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation